The Analysis of Gravity on Tourism Resource of Shijiazhuang with Anion, Hebei

AbstractThis paper analyzes the decisive factor of The Shijiazhuang coastal economic zone's tourist resource from the perspective of the actual data by adopting Gravity model; meanwhile, presents an overall aspect of Shijiazhuang city, its current development of the tourism industry, and the advantages and characteristics as well. Further proposal is also produced to contribute to the tourist development based on the analysis of the model data

Raw frozen Antarctic krill (Euphausia superba) as an alternative feed source for cuttlefish Sepiella japonica in artificial breeding systems

The study aims to evaluate the feasibility of completely replacing raw frozen shrimp Palaemon gravieri diets with raw frozen Antarctic krill (Euphausia superba) in the diets of cuttlefish Sepiella japonica. To address the knowledge gap, we conducted a 60‐day feeding trial. At the end of the experiment (day 60), the cuttlefish Sepiella japonica eating Palaemon gravieri (SJP) grew significantly faster than those eating Euphausia superba (SJE), with the specific growth rate (SGR)SJP (7.92%) > (SGR)SJE (7.09%). Approximately 33.3% and 20.0% mortality was observed in the SJE and SJP, during the course of the experiment respectively. Some important fatty acids (i.e. n‐3 and n‐6 PUFAs) were elevated in SJE with respect to SJP. Replacement of Antarctic krill increased the diversity of the gut microbiome composition in the SJE group. Fluoride accumulated in the ink sac and cuttlebone of cuttlefish in SJE. Overall, these findings imply that PUFA‐rich Antarctic krill could replace P. gravieri shrimp for feeding cuttlefish S. japonica

CURRENT STATUS ON HIGH PERFORMANCE COMPUTING FOR VEHICLE AERODYNAMICS USING LARGE EDDY SIMULATION

ABSTRACT The world's largest class unsteady turbulence simulations of flow around vehicles were conducted using Large Eddy Simulation (LES) on the Earth Simulator in Japan. The main objective of our study is to investigate the validity of LES, as an alternative to a conventional wind tunnel measurement or the Reynolds Averaged Navier-Stokes method, for the assessment of vehicle £ Address all correspondence to this author

Lack of Airborne Transmission during Outbreak of Pandemic (H1N1) 2009 among Tour Group Members, China, June 2009

This outbreak was caused by droplet transmission

Development of the Fluid Dynamics Simulation Software "FrontFlow/Red"

特集1 乱流シミュレーションと流れの設計(TSFD

Genetic heterogeneity in primary and relapsed mantle cell lymphomas : impact of recurrent CARD11 mutations

The genetic mechanisms underlying disease progression, relapse and therapy resistance in mantle cell lymphoma (MCL) remain largely unknown. Whole-exome sequencing was performed in 27 MCL samples from 13 patients, representing the largest analyzed series of consecutive biopsies obtained at diagnosis and/or relapse for this type of lymphoma. Eighteen genes were found to be recurrently mutated in these samples, including known (ATM, MEF2B and MLL2) and novel mutation targets (S1PR1 and CARD11). CARD11, a scaffold protein required for B-cell receptor (BCR)-induced NF-κB activation, was subsequently screened in an additional 173 MCL samples and mutations were observed in 5.5% of cases. Based on in vitro cell line-based experiments, overexpression of CARD11 mutants were demonstrated to confer resistance to the BCR-inhibitor ibrutinib and NF-κB-inhibitor lenalidomide. Genetic alterations acquired in the relapse samples were found to be largely non-recurrent, in line with the branched evolutionary pattern of clonal evolution observed in most cases. In summary, this study highlights the genetic heterogeneity in MCL, in particular at relapse, and provides for the first time genetic evidence of BCR/NF-κB activation in a subset of MCL

AUGMENT : a phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma

PURPOSE Patients with indolent non-Hodgkin lymphoma typically respond well to first-line immunochemotherapy. At relapse, single-agent rituximab is commonly administered. Data suggest the immunomodulatory agent lenalidomide could increase the activity of rituximab. METHODS A phase III, multicenter, randomized trial of lenalidomide plus rituximab versus placebo plus rituximab was conducted in patients with relapsed and/or refractory follicular or marginal zone lymphoma. Patients received lenalidomide or placebo for 12 cycles plus rituximab once per week for 4 weeks in cycle 1 and day 1 of cycles 2 through 5. The primary end point was progression-free survival per independent radiology review. RESULTS A total of 358 patients were randomly assigned to lenalidomide plus rituximab (n = 178) or placebo plus rituximab (n = 180). Infections (63% v 49%), neutropenia (58% v 23%), and cutaneous reactions (32% v 12%) were more common with lenalidomide plus rituximab. Grade 3 or 4 neutropenia (50% v 13%) and leukopenia (7% v 2%) were higher with lenalidomide plus rituximab; no other grade 3 or 4 adverse event differed by 5% or more between groups. Progression-free survival was significantly improved for lenalidomide plus rituximab versus placebo plus rituximab, with a hazard ratio of 0.46 (95% CI, 0.34 to 0.62; P < .001) and median duration of 39.4 months (95% CI, 22.9 months to not reached) versus 14.1 months (95% CI, 11.4 to 16.7 months), respectively. CONCLUSION Lenalidomide improved efficacy of rituximab in patients with recurrent indolent lymphoma, with an acceptable safety profile

The prognostic index PRIMA-PI combined with Ki67 as a better predictor of progression of disease within 24 months in follicular lymphoma

BackgroundProgression of disease within 24 months (POD24) is a risk factor for poor survival in follicular lymphoma (FL), and there is currently no optimal prognostic model to accurately predict patients with early disease progression. How to combine traditional prognostic models with new indicators to establish a new prediction system, to predict the early progression of FL patients more accurately is a future research direction.MethodsThis study retrospectively analyzed patients with newly diagnosed FL patients in Shanxi Provincial Cancer Hospital from January 2015 to December 2020. Data from patients undergoing immunohistochemical detection (IHC) were analyzed using χ2 test and multivariate Logistic regression. Also, we built a nomogram model based on the results of LASSO regression analysis of POD24, which was validated in both the training set and validation set, and additional external validation was performed using a dataset (n = 74) from another center, Tianjin Cancer Hospital.ResultsThe multivariate Logistic regression results suggest that high-risk PRIMA-PI group, Ki-67 high expression represent risk factors for POD24 (P&lt;0.05). Next, PRIMA-PI and Ki67 were combined to build a new model, namely, PRIMA-PIC to reclassify high and low-risk groups. The result showed that the new clinical prediction model constructed by PRIMA-PI with ki67 has a high sensitivity to the prediction of POD24. Compared to PRIMA-PI, PRIMA-PIC also has better discrimination in predicting patient’s progression-free survival (PFS) and overall survival (OS). In addition, we built nomogram models based on the results of LASSO regression (histological grading, NK cell percentage, PRIMA-PIC risk group) in the training set, which were validated using internal validation set and external validation set, we found that C-index and calibration curve showed good performance.ConclusionAs such, the new predictive model-based nomogram established by PRIMA-PI and Ki67 could well predict the risk of POD24 in FL patients, which boasts clinical practical value

Extracellular Tau Oligomers Produce An Immediate Impairment of LTP and Memory

Non-fibrillar soluble oligomeric forms of amyloid-\u3b2 peptide (oA\u3b2) and tau proteins are likely to play a major role in Alzheimer's disease (AD). The prevailing hypothesis on the disease etiopathogenesis is that oA\u3b2 initiates tau pathology that slowly spreads throughout the medial temporal cortex and neocortices independently of A\u3b2, eventually leading to memory loss. Here we show that a brief exposure to extracellular recombinant human tau oligomers (oTau), but not monomers, produces an impairment of long-term potentiation (LTP) and memory, independent of the presence of high oA\u3b2 levels. The impairment is immediate as it raises as soon as 20\u2009min after exposure to the oligomers. These effects are reproduced either by oTau extracted from AD human specimens, or naturally produced in mice overexpressing human tau. Finally, we found that oTau could also act in combination with oA\u3b2 to produce these effects, as sub-toxic doses of the two peptides combined lead to LTP and memory impairment. These findings provide a novel view of the effects of tau and A\u3b2 on memory loss, offering new therapeutic opportunities in the therapy of AD and other neurodegenerative diseases associated with A\u3b2 and tau pathology